The tert-butyl dimethyl silyl group as an enhancer of drug cytotoxicity against human tumor cells

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 15, 2005, Pages 3536-3539

  Donadel, Osvaldo J ^a,b   Martín, Tomás ^a   Martín, Víctor S ^a   Villar, Jesús ^c   Padrón, José M ^a,c,d  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d Red Tematica de Investigacion Cooperativa en Cancer   (Spain)

Author keywords

Breast cancer; Leukemia; Silyl ethers; Tetrahydropyran

Indexed keywords

ACETIC ACID; ALLYL COMPOUND; BENZOIC ACID; HYDROXYL GROUP; PYRAN DERIVATIVE; SILANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN HL 60; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENANTIOMER; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUMOR CELL;

ACETATES; ALLYL COMPOUNDS; ANTINEOPLASTIC AGENTS; BENZOATES; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA; ORGANOSILICON COMPOUNDS; PHARMACEUTICAL PREPARATIONS; PYRANS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 21744451934     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.05.126     Document Type: Article

References (18)

1. A.M. Bergman, C.M. Kuiper, F. Myhren, M.L. Sandvold, H.R. Hendriks, and G.J. Peters Nucleosides Nucleotides Nucleic Acids 23 2004 1523
2. A.M. Bergman, C.M. Kuiper, D.A. Voorn, E.M. Comijn, F. Myhren, M.L. Sandvold, H.R. Hendriks, and G.J. Peters Biochem. Pharmacol. 67 2004 503
3. A.M. Bergman, C.M. Kuiper, P. Noordhuis, K. Smid, D.A. Voorn, E.M. Comijn, F. Myhren, M.L. Sandvold, H.R. Hendriks, O. Fodstad, K. Breistol, and G.J. Peters Nucleosides Nucleotides Nucleic Acids 23 2004 1329
4. G. Kokotos, V. Theodorou, V. Constantinou-Kokotou, W.A. Gibbons, and C. Roussakis Bioorg. Med. Chem. Lett. 8 1998 1525
5. J.-P. Souchard, T.T. Ha, S. Cros, and N.P. Johnson J. Med. Chem. 34 1991 863
6. I. Iovel, L. Golomba, L. Zvejniece, I. Shestakova, and E. Lukevics Chem. Heterocycl. Compd. 39 2003 449
7. W.-M. Dai, Y. Tachi, S.-I. Nishimoto, X. Zhong, and Z. Guo Lett. Drug Des. Discov. 1 2004 69
8. W. Anderson, R. Kasliwal, D.M. Houston, Y.-S. Wang, V.L. Narayanan, R.D. Haugwitz, and J. Plowman J. Med. Chem. 38 1995 3789
9. A.M. Van Hattum, H.M. Pinedo, H.M.M. Schlüper, F.H. Hausheer, and E. Boven Int. J. Cancer 88 2000 260
10. J.M. Betancort, T. Martín, J.M. Palazón, and V.S. Martín J. Org. Chem. 69 2003 3216
11. K.C. Nicolaou, C.-K. Hwang, B.E. Marron, S.A. DeFress, E.A. Couladouros, Y. Abe, P.J. Carroll, and J.P. Snyder J. Am. Chem. Soc. 112 1990 3040
12. K. Ando Tetrahedron Lett. 36 1995 4105
13. All intermediates and final products gave satisfactory analytical and spectroscopic data in full accord with their assigned structures.
14. Y.P. Keepers, P.E. Pizao, G.J. Peters, J. Van Ark-Otte, and B. Winograd Eur. J. Cancer 27 1991 897
15. P. Skehan, P. Storeng, D. Scudeiro, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1107
16. Pure compounds were initially dissolved in DMSO at 400 times the desired final maximum test concentration, that is, 100 μM. Control cells were exposed to an equivalent concentration of DMSO. Each agent was tested in duplicate at five different 10-fold dilutions. Drug incubation times were 48 h, after which cells were precipitated with 50 μL ice-cold 80% (w/v) trichloroacetic acid (HL60) or 25 μL ice-cold 50% (w/v) trichloroacetic acid (MCF7) and fixed for 60 min at 4°C. Then the SRB assay was performed. The optical density (OD) of each well was measured at 490 nm using Bio-Tek's Elx800 NB 96-well plate reader. The percentage growth was calculated at each of the drug concentration levels based on the difference in OD at the start and end of drug exposure. Values were corrected for background OD from wells only containing medium.
17. Software-predicted lipophilicity of the compounds was calculated with the program CLOGP accessible via Internet (www.daylight.com/daycgi/clogp ) working with the Hansch-Leo's "fragment constant" method.
18. For a comparison study with other computer programs see: S.G. Machatha, and S.H. Yalkowsky Int. J. Pharm. 294 2005 185